2018年英國(guó)指南解讀 《特發(fā)性顱內(nèi)高壓癥:管理共識(shí)指南》 Idiopathic intracranial hypertension: consensusguidelines on management-2018 作者:丁江偉 寧夏醫(yī)科大學(xué)寧夏顱腦疾病重點(diǎn)實(shí)驗(yàn)室 寧夏醫(yī)科大學(xué)總醫(yī)院神經(jīng)外科 圖1 IIH診療共識(shí)。 IIH患者的管理,需多學(xué)科醫(yī)師進(jìn)行評(píng)估,以便聯(lián)合制定最佳診療方案(圖4),主要管理原則為: Cochrane一項(xiàng)綜述報(bào)道了乙酰唑胺(一種碳酸酐酶抑制劑)在IIH中的應(yīng)用,結(jié)論指出“包括RCT(RandomizedControlled Trial)在內(nèi)的兩項(xiàng)研究均顯示乙酰唑胺對(duì)IIH的某些臨床癥狀有一定益處,但仍無(wú)充足的證據(jù)推薦或拒絕該藥或其他藥物對(duì)IIH患者的療效”[16]。 目前尚無(wú)乙酰唑胺的最佳服用劑量。 除乙酰唑胺外,托吡酯可能對(duì)IIH頭痛有一定效果[19]。 IIH的頭痛類型常隨時(shí)間而改變,需仔細(xì)評(píng)估。頭痛常為混合型:包括IIH引起的頭痛、偏頭痛、藥物過(guò)量誘發(fā)的頭痛、緊張型頭痛、低顱壓頭痛和腦脊液分流繼發(fā)醫(yī)源性Chiari畸形引起頭痛等[23, 24]。 據(jù)報(bào)道68% IIH患者的頭痛屬于偏頭痛[25],盡管缺乏臨床試驗(yàn),但對(duì)IIH患者使用偏頭痛治療方案可能是有效的。偏頭痛的特征包括中度至重度疼痛,可能伴有畏光、恐聲、惡心和運(yùn)動(dòng)不耐受。 若視神經(jīng)乳頭水腫已消退,通常情況下顱內(nèi)壓將正?;?,此時(shí)應(yīng)采用保守治療。 如果妊娠期間IIH急性加重,存在視力緊急受損的風(fēng)險(xiǎn)該如何處理? 參考文獻(xiàn): [1].Markey K, Mollan S, Jensen R ,et al. Understanding idiopathicintracranial hypertension: mechanisms, management, and future directions[J].Lancet Neurol. 2016,15(1):78-91. doi:10.1016/s1474-4422(15)00298-7. [2].由春梅,周菲, 黃流清. 特發(fā)性顱高壓癥的研究進(jìn)展[J]. 中華神經(jīng)醫(yī)學(xué)雜志. 2018,8(17):856-62. [3].MollanS, Davies B, Silver N ,et al. Idiopathic intracranial hypertension: consensusguidelines on management[J]. J Neurol Neurosurg Psychiatry.2018,89(10):1088-100. doi:10.1136/jnnp-2017-317440. [4].FriedmanD, Liu G, Digre K. Revised diagnostic criteria for the pseudotumor cerebri syndromein adults and children[J]. Neurology. 2013,81(13):1159-65.doi:10.1212/WNL.0b013e3182a55f17. [5].DigreK, Nakamoto B, Warner J ,et al. A comparison of idiopathic intracranialhypertension with and without papilledema[J]. Headache. 2009,49(2):185-93.doi:10.1111/j.1526-4610.2008.01324.x. [6].WheltonP, Carey R, Aronow W ,et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,Detection, Evaluation, and Management of High Blood Pressure in Adults:Executive Summary: A Report of the American College of Cardiology/AmericanHeart Association Task Force on Clinical Practice Guidelines[J]. Hypertension2018,71(6):1269-324. doi:10.1161/hyp.0000000000000066. [7].SinclairA, Burdon M, Nightingale P ,et al. Low energy diet and intracranial pressure inwomen with idiopathic intracranial hypertension: prospective cohort study[J].BMJ. 2010,341:c2701. doi:10.1136/bmj.c2701. [8].UretskyS. Surgical interventions for idiopathic intracranial hypertension[J]. CurrOpin Ophthalmol. 2009,20(6):451-5. doi:10.1097/ICU.0b013e3283313c1c. [9].KalyvasA, Hughes M, Koutsarnakis C ,et al. Efficacy, complications and cost ofsurgical interventions for idiopathic intracranial hypertension: a systematicreview of the literature[J]. Acta neurochirurgica. 2017,159(1):33-49.doi:10.1007/s00701-016-3010-2. [10].王玉社,陳航, 王勇 ,et al. B超引導(dǎo)下腦室-腹腔分流術(shù)治療特發(fā)性顱高壓療效分析[J]. 中華醫(yī)學(xué)雜志. 2016,23(96):1856-8. [11].SpitzeA, Malik A, Al-Zubidi N ,et al. Optic nerve sheath fenestration vscerebrospinal diversion procedures: what is the preferred surgical procedurefor the treatment of idiopathic intracranial hypertension failing maximummedical therapy?[J]. J Neuroophthalmol 2013,33(2):183-8.doi:10.1097/WNO.0b013e318292d06f. [12].BonoF, Quattrone A. Clinical course of idiopathic intracranial hypertension withtransverse sinus stenosis[J]. Neurology. 2013,81(7):695.doi:10.1212/01.wnl.0000433838.88247.f3. [13].郭新賓,魏森, 孫曉禎 ,et al. 特發(fā)性顱內(nèi)高壓患者清醒和全身麻醉狀態(tài)下顱內(nèi)靜脈壓的比較研究[J]. 中華神經(jīng)醫(yī)學(xué)雜志. 2020,9(19):958-60. [14].李克,王立艷, 孟然 ,et al. 特發(fā)性顱高壓靜脈竇狹窄腔內(nèi)介入治療進(jìn)展[J]. 中國(guó)腦血管病雜志. 2019,2(16):109-12,封3. [15].DuitsF, Martinez-Lage P, Paquet C ,et al. Performance and complications of lumbarpuncture in memory clinics: Results of the multicenter lumbar puncturefeasibility study[J]. Alzheimers Dement. 2016,12(2):154-63.doi:10.1016/j.jalz.2015.08.003. [16].PiperR, Kalyvas A, Young A ,et al. Interventions for idiopathic intracranial hypertension[J].Acta Neurochir. 2015(8):CD003434. doi:10.1002/14651858.CD003434.pub3. [17].tenHove M, Friedman D, Patel A ,et al. Safety and Tolerability of Acetazolamide inthe Idiopathic Intracranial Hypertension Treatment Trial[J]. J Neuroophthalmol2016,36(1):13-9. doi:10.1097/wno.0000000000000322. [18].BallA, Howman A, Wheatley K ,et al. A randomised controlled trial of treatment foridiopathic intracranial hypertension[J]. J Neurol. 2011,258(5):874-81.doi:10.1007/s00415-010-5861-4. [19].SilbersteinS. Topiramate in Migraine Prevention: A 2016 Perspective[J]. Headache2017,57(1):165-78. doi:10.1111/head.12997. [20].HeadacheClassification Committee of the International Headache Society (IHS).TheInternational Classification of Headache Disorders, 3rd edition (betaversion)[J]. Cephalalgia 2013,33(9):629-808. doi:10.1177/0333102413485658. [21].SaderN, Zeiler F, Gillman L ,et al. Indomethacin for control of ICP[J]. NeurocritCare 2015,22(3):437-49. doi:10.1007/s12028-014-0088-3. [22].CentreN. Headaches: Diagnosis and Management of Headaches in Young People andAdults[J]. Pediatrics. 2012. [23].FriedmanD, Rausch E. Headache diagnoses in patients with treated idiopathicintracranial hypertension[J]. Neurology. 2002,58(10):1551-3.doi:10.1212/wnl.58.10.1551. [24].MengerRP, Connor DE, Thakur JD ,et al. A comparison of lumboperitoneal andventriculoperitoneal shunting for idiopathic intracranial hypertension: ananalysis of economic impact and complications using the Nationwide InpatientSample[J]. Neurosurgical Focus. 2014,37(5):E4. [25].FriedmanD, Quiros P, Subramanian P ,et al. Headache in Idiopathic Intracranial Hypertension:Findings From the Idiopathic Intracranial Hypertension Treatment Trial[J].Headache. 2017,57(8):1195-205. doi:10.1111/head.13153. [26].KennisK, Kernick D, O'Flynn N. Diagnosis and management of headaches in young peopleand adults: NICE guideline[J]. The British journal of general practice : thejournal of the Royal College of General Practitioners. 2013,63(613):443-5.doi:10.3399/bjgp13X670895. [27].deGoffau M, Klaver A, Willemsen M ,et al. The Effectiveness of Treatments forPatients With Medication Overuse Headache: A Systematic Review andMeta-Analysis[J]. J Pain 2017,18(6):615-27. doi:10.1016/j.jpain.2016.12.005. [28].SilbersteinS. Topiramate in Migraine Prevention: A 2016 Perspective[J]. Headache.2017,57(1):165-78. doi:10.1111/head.12997. [29].AuroraS, Dodick D, Diener H ,et al. OnabotulinumtoxinA for chronic migraine:efficacy, safety, and tolerability in patients who received all five treatmentcycles in the PREEMPT clinical program[J]. Acta neurologica Scandinavica.2014,129(1):61-70. doi:10.1111/ane.12171. [30].deSouzaR, Toma A, Watkins L. Medication overuse headache - An under-diagnosed problemin shunted idiopathic intracranial hypertension patients[J]. Br J Neurosurg 2015,29(1):30-4.doi:10.3109/02688697.2014.950633. [31].ZeebergP, Olesen J, Jensen R. Discontinuation of medication overuse in headachepatients: recovery of therapeutic responsiveness[J]. Cephalalgia 2006,26(10):1192-8.doi:10.1111/j.1468-2982.2006.01190.x. [32].LiuA, Elder B, Sankey E ,et al. Are shunt series and shunt patency studies usefulin patients with shunted idiopathic intracranial hypertension in the emergencydepartment?[J]. Clin Neurol Neurosurg 2015,138:89-93.doi:10.1016/j.clineuro.2015.08.008. [33].LiuA, Elder B, Sankey E ,et al. The Utility of Computed Tomography in ShuntedPatients with Idiopathic Intracranial Hypertension Presenting to the EmergencyDepartment[J]. World Neurosurg. 2015,84(6):1852-6.doi:10.1016/j.wneu.2015.08.008. [34].WillerL, Jensen R, Juhler M. Medication overuse as a cause of chronic headache inshunted hydrocephalus patients[J]. J Neurol Neurosurg Psychiatry.2010,81(11):1261-4. doi:10.1136/jnnp.2009.198101. [35].BruceB, Digre K, McDermott M ,et al. Quality of life at 6 months in the IdiopathicIntracranial Hypertension Treatment Trial[J]. Neurology. 2016,87(18):1871-7.doi:10.1212/wnl.0000000000003280. [36].ThurtellM, Trotti L, Bixler E ,et al. Obstructive sleep apnea in idiopathicintracranial hypertension: comparison with matched population data[J]. Journalof neurology. 2013,260(7):1748-51. doi:10.1007/s00415-013-6858-6. [37].GlueckC, Iyengar S, Goldenberg N ,et al. Idiopathic intracranial hypertension: associationswith coagulation disorders and polycystic-ovary syndrome[J]. J Lab Clin Med.2003,142(1):35-45. doi:10.1016/s0022-2143(03)00069-6. [38].YriH, Fagerlund B, Forchhammer H ,et al. Cognitive function in idiopathicintracranial hypertension: a prospective case-control study[J]. BMJ open.2014,4(4):e004376. doi:10.1136/bmjopen-2013-004376. [39].FalardeauJ, Lobb B, Golden S ,et al. The use of acetazolamide during pregnancy inintracranial hypertension patients[J]. J Neuroophthalmol. 2013,33(1):9-12.doi:10.1097/WNO.0b013e3182594001. [40].WestonJ, Bromley R, Jackson C ,et al. Monotherapy treatment of epilepsy in pregnancy:congenital malformation outcomes in the child[J]. Cochrane Database Syst Rev.2016,11:CD010224. doi:10.1002/14651858.CD010224.pub2. [41].ACOGCommittee opinion no. 548: weight gain during pregnancy[J]. Obstetrics andgynecology. 2013,121(1):210-2. doi:10.1097/01.aog.0000425668.87506.4c. [42].DigreK, Nakamoto B, Warner J ,et al. A comparison of idiopathic intracranialhypertension with and without papilledema[J]. Headache. 2009,49(2):185-93.doi:10.1111/j.1526-4610.2008.01324.x. [43].ChackoJ. Optic nerve sheath diameter: An ultrasonographic window to view raisedintracranial pressure?[J]. Indian J Crit Care Med. 2014,18(11):707-8. doi:10.4103/0972-5229.144007.
|
|
來(lái)自: 新用戶0125i6lE > 《待分類》